Funding and capital access
The company needs external financing to fund research, regulatory work, and market expansion
- Scope
- Corporate strategy execution
- Materiality
- high
Enzymatica
Enzymatica is a Swedish life science company that develops and sells medical products for infection-related conditions based on its Penzyme barrier technology. Its core product is ColdZyme, a mouth spray for colds and cold-like symptoms, and the business is organized around in-house enzyme production, regulatory know-how, and partner-led commercialization in selected markets.
| % | |
|---|---|
| ColdZyme consumer health products | 85% Mouth spray products based on barrier technology for colds and cold-like symptoms. |
| Enzyme production and technology platform | 10% Internal production of marine enzymes and related know-how that support the product platform. |
| Regulatory and clinical support | 5% Documentation, approvals, and scientific support used to maintain market access and partnerships. |
Enzymatica sells primarily into consumer health channels, where end users buy ColdZyme for relief from colds and upper...
- Consumers with cold and cold-like symptomsprimary
Buy ColdZyme for symptom relief and convenience in self-care settings
- Consumer health partners and distributorsprimary
Buy rights, supply, and support to market and distribute ColdZyme locally
- Pharmacy and retail channelssecondary
Stock the product for over-the-counter consumer purchase and repeat use
- Direct-market consumers in owned marketssecondary
Purchase through markets where Enzymatica manages sales and marketing directly
Enzymatica is headquartered in Lund, Sweden, with key operational functions also in Reykjavik, Iceland...
- •Headquartered in Lund, Sweden
- •Enzyme production facility in Reykjavik, Iceland
- •Direct sales and marketing in Sweden, the UK, and Iceland
- •Partner-led expansion in selected EEA markets
- •International launches depend on local regulation and approvals
Enzymatica’s strategy is built around expanding through local partners, relaunching ColdZyme in markets where it...
01
Partner-led international expansionmedium-term
Local partners provide market access, sales capability, and regulatory familiarity without requiring a large local footprint
02
Relaunch in selected EEA marketsshort-term
Existing MDR approvals can shorten time to market and improve the economics of re-entry
03
Product portfolio developmentmedium-term
A broader portfolio can reduce dependence on a single product and extend the barrier-technology platform
04
Scientific and regulatory validationshort-term
Clinical evidence and documentation support approvals, partner discussions, and consumer trust
Enzymatica depends on external financing, partner execution, and continued regulatory acceptance in markets where...
Partner distribution dependence
Sales in many markets rely on third-party partners, so weak partner execution directly limits revenue
- Scope
- International commercialization
- Materiality
- high
Regulatory and classification risk
Medical-device rules, approvals, and product classification can change market access and documentation needs
- Scope
- EU/EEA and other regulated markets
- Materiality
- high
Competition
Larger rivals may offer stronger brands, lower prices, or more effective products
- Scope
- Cold-remedy consumer health markets
- Materiality
- medium
Cybersecurity and IT disruption
Production, quality, and communication depend on functioning systems and data protection
- Scope
- Operations and compliance
- Materiality
- medium
Production and supply-chain dependence
The model combines in-house enzyme production with external filling and packaging partners
- Scope
- Manufacturing and fulfillment
- Materiality
- medium
Development cost capitalization
Can materially affect operating profit and balance-sheet intangibles
Goodwill impairment testing
Impairment could reduce equity and earnings materially
Foreign currency translation
Can create volatility in reported results and equity reserves
Contract manufacturing and inventory timing
Can influence gross margin and inventory valuation
: 11/08/2026